Active Biotech Appoints Erik Vahtola as Chief Medical Officer
Lund, January 4, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that Dr. Erik Vahtola, MD, PhD, has been appointed Chief Medical Officer (CMO), effective January 1, 2022. He will join the executive management team and be responsible for the development of the company´s clinical project portfolio within solid and hematological cancers, and inflammatory eye disorders.
Dr. Vahtola has more than 10 years of experience altogether from regulatory authority and pharma industry positions within clinical development and medical affairs. Before joining Active Biotech, he has worked at Bayer Pharmaceuticals, Orion Corporation and Roche Pharma, Finland. As a Medical Doctor (MD) he has experience from working as a specializing physician in oncology at the Helsinki University Central Hospital, Finland and he holds a PhD in pharmacology and an MSc in cell biology from Åbo Akademi University, Finland.
“We are happy to welcome Erik to Active Biotech. This appointment marks an important step in the continued development of the company's project portfolio with three projects now in clinical development. Erik’s medical expertise and experience will further strengthen the team as our project portfolio progresses into later clinical phases”, said Dr. Helén Tuvesson, CEO of Active Biotech.
“I am excited to join Active Biotech at this important stage, where the company has advanced the clinical development of its exciting leading candidate drugs in both oncology and inflammatory eye diseases”, said Erik Vahtola.
Dr. Helena Eriksson, CSO and responsible for Research and Development since 2017, has decided to leave her position after 23 years in the company, but she will continue as a consultant to Active Biotech with a focus on scientific and patent-related issues.
“Helena, with her deep biological understanding, has been instrumental in the implementation of the company's new focus on projects in specialist indications with high medical need and a commercial opportunity. I would like to thank Helena for her commitment and engagement in the development of our projects, and I am very happy that we will continue to work together”, said Helen Tuvesson.
For further information, please contact:
Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com
About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. The small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II for treatment of non-infectious uveitis. Please visit www.activebiotech.com for more information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Scheelevägen 22, SE-223 63 Lund, Sweden
Tel: +46 (0)46 19 20 00
This information is information was submitted for publication, through the agency of the contact person set out above, at 14.00 pm CET on January 4, 2022.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Auriant Mining AB (publ.) Årsredovisningen för 202323.4.2024 15:28:05 CEST | Pressemelding
Årsredovisningen kan laddas ned från bolagets hemsida: https://www.auriant.com/sw/investor-relations/#section-reports-and-releases Den tryckta versionen av årsredovisningen kan beställas via telephone +46 707 277 097 eller via e-post: ir@auriant.com. För mer information, vänligen kontakta: Danilo Lange, VD Tel: +7 495 109 02 82 E-post: d.lange@auriant.com Företagsnamn: Auriant Mining AB Kortnamn: AUR ISIN-kod: SE0001337213 Webbplats: www.auriant.com Auriant Mining AB (AUR) är ett svenskt gruvbolag med inriktning på prospektering och guldproduktion i Ryssland, främst i republiken Tyva, Zabaikalye och republiken Khakassia. Bolaget har för närvarande fyra licenser, inklusive två gruvor i drift (Tardan och Alluvial vid Staroverinskaya), en prospekteringstillgång i ett tidigt skede och en prospekteringstillgång under utveckling. Sedan den 19 juli 2010 handlas Auriants aktier på First North Premier vid NASDAQ Nordic Exchange under beteckningen AUR. Läs mer på www.auriant.com. G&W Fondkommiss
Auriant Mining AB (publ.) Annual Report for 202323.4.2024 15:28:05 CEST | Press release
The annual report can be downloaded from the Company’s website: https://www.auriant.com/investor-relations/#section-reports-and-releases The printed version of the Annual Report can be ordered by telephone +46 707 277 097 or by e-mail: ir@auriant.com. For more information, please contact: Danilo Lange, CEO Tel.: +7 495 109 02 82 E-mail: d.lange@auriant.com Company name: Auriant Mining AB Short name: AUR ISIN-code: SE0001337213 Website: www.auriant.com Auriant Mining AB (AUR) is a Swedish junior mining company focused on gold exploration and production in Russia, primarily in the Republic of Tyva, Zabaikalye and the Republic of Khakassia. The company has currently four assets, including two operating mines (Tardan and Alluvial at Staroverinskaya), one early stage exploration asset and one development asset. Since July 19, 2010, Auriant Mining´s shares are traded on Nasdaq First North Premier Growth Market under the short name AUR. For more information, please visit www.auriant.com. G&W
Welltec Q1 2024 Interim Report and Investor Conference Call Announcement23.4.2024 15:23:43 CEST | Press release
Q1 2024 Interim Report and Investor Conference Call Announcement Welltec® will disclose its Q1 2024 Interim Report and will discuss the results during an investor conference call to be held Wednesday, May 15th, 2024, at 5 pm CEST. The conference call will be available only to current and prospective bond holders, broker dealers, and securities analysts, and can be accessed by dialing in a few minutes before the start and informing the operator that you would like to participate in Welltec’s investor conference call. Relevant dial-in details and conference ID can be obtained by contacting Kris Petrov krpetrov@welltec.com and registering for the call. Registration will not be possible once the investor conference has started. The Q1 2024 Interim Report will be made available in the “Investor Room” on Welltec’s website at http://www.welltec.com/investors. For further information, please contact: Kris Petrov, Finance Director Cell: +45 48 14 35 14 E-mail: krpetrov@welltec.com Company Profi
Uhnder Releases New 4D Digital Imaging Radar Chip to Bolster ADAS Applications for Mass Market Automobiles23.4.2024 15:00:30 CEST | Press release
AUSTIN, Texas, April 23, 2024 (GLOBE NEWSWIRE) -- Uhnder Inc., headquartered in Austin, Texas and renowned for its digital radar technology, is excited to unveil the commercial availability of its latest innovation, the S81 mass market imaging radar solution. Traditionally, the exorbitant costs of 4D imaging radars limited their enhanced safety benefits to high-end automobiles. However, the S81 revolutionizes this landscape by offering a compact 4D single-chip solution at an attractive price point, made possible by its utilization of Digital Code Modulation (DCM). This breakthrough drastically reduces the cost barrier for Advanced Driver Assistance Systems (ADAS) and will catalyze the widespread adoption of this highly sought-after technology. Featuring support for up to 96 MIMO channels, the S81 boasts exceptional High Contrast Resolution (HCR), enabling precise discrimination between closely positioned objects. Moreover, it establishes a new benchmark for interference mitigation and
TMC & SGS Produce World-First Nickel Sulfate from Deep-Seafloor Polymetallic Nodules23.4.2024 14:00:41 CEST | Press release
As part of TMC’s pilot-scale nodule processing, SGS and TMC produced the world's first nickel sulfate from deep-seafloor polymetallic nodules, indicating TMC’s resource is suitable for battery marketsThe nickel sulfate was produced in a testing program conducted in collaboration with SGS and other industry leaders applying TMC’s efficient flowsheet design that processes high-grade nickel matte direct to nickel sulfate (without making nickel metal) and produces fertilizer products instead of solid waste or tailingsTMC holds exploration rights to the world's two largest-ranked undeveloped nickel deposits, which could offer a less impactful alternative to market dominant rainforest-sourced nickel laterites, potentially alleviating stress on ecosystems and local communities NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- TMC the metals company Inc. (Nasdaq: TMC) (“TMC” or the “Company”), an explorer of the world’s largest estimated undeveloped source of critical battery metals, today announce